Do Schizophrenics Well Adapted in the Community Need Neuroleptics? A Depot Neuroleptic Withdrawal Study
Overview
Authors
Affiliations
Two depot neuroleptics (flupenthixol plamitate and clopenthixol decanoate) used for at least 15 months were withdrawn in 32 schizophrenic outpatients belonging to the most symptom-free and social cohort of a total patient population. They all had only slight schizophrenic symptoms, were well adapted in the community, and had been free from relapse for at least 2 years before the study. They were assessed by means of rating scales every month during the first six months and then after 9 and 12 months. After the one-year trial 26 patients had relapsed. Moreover, after the control period further 4 out of 6 patients relapsed during the following drug-free year. These results indicate the necessity of a long follow-up period after withdrawal of depot neuroleptics. Moreover, the results suggest that periodical drug-free periods of about 3 months are appropriate in symptom-poor patients during long-term treatment with long-acting antipsychotic drugs.
Fluphenazine (oral) versus placebo for schizophrenia.
Matar H, Almerie M, Sampson S Cochrane Database Syst Rev. 2018; 6:CD006352.
PMID: 29893410 PMC: 6513420. DOI: 10.1002/14651858.CD006352.pub3.
Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Maayan N, Quraishi S, David A, Jayaswal A, Eisenbruch M, Rathbone J Cochrane Database Syst Rev. 2015; (2):CD000307.
PMID: 25654768 PMC: 10388394. DOI: 10.1002/14651858.CD000307.pub2.
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.
Mahapatra J, Quraishi S, David A, Sampson S, Adams C Cochrane Database Syst Rev. 2014; (6):CD001470.
PMID: 24915451 PMC: 7057031. DOI: 10.1002/14651858.CD001470.pub2.
Fluphenazine (oral) versus placebo for schizophrenia.
Matar H, Almerie M, Sampson S Cochrane Database Syst Rev. 2013; (7):CD006352.
PMID: 23861067 PMC: 3997140. DOI: 10.1002/14651858.CD006352.pub2.
Depot fluspirilene for schizophrenia.
Abhijnhan A, Adams C, David A, Ozbilen M Cochrane Database Syst Rev. 2007; (1):CD001718.
PMID: 17253464 PMC: 7025783. DOI: 10.1002/14651858.CD001718.pub2.